Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeiGene Ltd ( (HK:6160) ) has shared an update.
BeOne Medicines Ltd., a Swiss corporation, announced the grant of Restricted Share Units (RSUs) and Performance Share Units (PSUs) under its 2016 Share Option and Incentive Plan. On September 30, 2025, the company’s compensation committee granted 36,234 RSUs to 237 grantees and 2,935 PSUs to one grantee, representing approximately 0.03% of the total issued shares. This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially impacting its operational dynamics and stakeholder interests positively.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,257,827
Technical Sentiment Signal: Buy
Current Market Cap: HK$331.1B
See more data about 6160 stock on TipRanks’ Stock Analysis page.